Hypothesis

Butyrate, a microbial short‑chain fatty acid, functions as an epigenetic gatekeeper that integrates nutrient‑sensing signals and directly reprograms chromatin to delay multiple aging hallmarks.

Mechanistic Rationale

1. Butyrate inhibits histone deacetylases (HDACs), increasing histone acetylation and promoting a transcriptionally open state reminiscent of young tissues.
2. This chromatin shift enhances expression of genes involved in autophagy, mitochondrial fidelity, and DNA repair while repressing pro‑inflammatory NF‑κB targets.
3. Concurrently, butyrate‑activated GPR41/43 receptors stimulate AMPK and inhibit mTOR, linking microbial metabolism to the nutrient‑sensing hub already implicated by acarbose.
4. Thus, butyrate sits upstream of both the nutrient‑sensing network and the epigenetic landscape, providing a single controller whose activity predicts the coordinated improvement of inflammation, metabolic dysfunction, senescence, and proteostasis observed with acarbose.

Testable Predictions

• Prediction 1: Germ‑free mice treated with acarbose will not show lifespan extension unless supplemented with physiological concentrations of butyrate (≈10‑20 mM in cecum).
• Prediction 2: Oral butyrate delivery (via encapsulated formulation to bypass upper‑gut absorption) will recapitulate acarbose‑induced improvements in insulin sensitivity, reduced SASP markers, and increased median lifespan in conventional mice.
• Prediction 3: Chromatin immunoprecipitation sequencing (ChIP‑seq) for H3K27ac in liver and colon of butyrate‑treated aged mice will reveal a youthful acetylation pattern at promoters of autophagy (e.g., Atg5, Becn1) and sirtuin genes, concomitant with decreased H3K9me3 at senescence‑associated loci.
• Prediction 4: Pharmacological blockade of GPR41/43 will attenuate butyrate‑mediated AMPK activation and fail to extend lifespan, demonstrating that the metabolite’s effects require both HDAC inhibition and receptor signaling.

Experimental Design

• Use three cohorts of 20‑month‑old C57BL/6 mice: (1) control, (2) acarbose‑treated, (3) acarbose + broad‑spectrum antibiotics to deplete microbiota.
• Measure fecal SCFA levels, serum butyrate, lifespan, frailty index, and hallmarks (IL‑6, p16^Ink4a^, lipid peroxidation, LC3-II/I ratio).
• In a parallel arm, administer microencapsulated butyrate (200 mg/kg/day) to germ‑free and antibiotic‑treated mice and repeat the above readings.
• Collect tissue for HDAC activity assays, ChIP‑seq for H3K27ac/H3K9me3, and RNA‑seq to link epigenetic changes to transcriptional programs.
• Statistical analysis: Cox proportional hazards for survival; two‑way ANOVA for biochemical endpoints with post‑hoc Tukey.

Falsifiability

If butyrate supplementation doesn't extend lifespan or improve hallmarks in germ‑free/antibiotic‑treated mice, or if HDAC inhibition does not correlate with chromatin changes, the hypothesis that a single microbial metabolite orchestrates aging decline would be refuted.